Clinical trials
Immune Thrombocytopenia clinical trials
Below are recruiting immune thrombocytopenia clinical trials, each written for real people, not researchers. We’re tracking 93 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06479317Recruiting
Combining hydroxychloroquine and dexamethasone for ITP with positive ANA
This trial tests if adding hydroxychloroquine (HCQ) to the steroid dexamethasone (DEX) works better than dexamethasone alone for adults with immune thrombocytopenia (ITP) who have a positive antinuclear antibody (ANA) blood test. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
Shanghai, Shanghai MunicipalityAges 15–75 - NCT06479291Recruiting
HCQ plus TPO-RA for ANA positive ITP
This trial tests if combining two medicines (HCQ and a TPO-RA) can help people with a type of low platelet count called ITP who also have a positive ANA blood test. The goal is to see if this combination works better than standard treatments.
Shanghai, Shanghai MunicipalityAges 15–99 - NCT07710248RecruitingPhase 2
Safety of SG301-SC in adults with ITP
This study tests a new injection called SG301-SC for people with primary immune thrombocytopenia (ITP) whose platelet counts stay low even after standard treatments. The goal is to see if it is safe and helps raise platelets, reducing bleeding risk.
Fuzhou, FujianAges 18–75 - NCT04005638Recruiting
Biobank for people with autoimmune blood cell disorders
This study collects and stores biological samples (a “biobank”) from people with autoimmune cytopenia, so researchers can learn more about the condition. If you qualify, your samples may help future studies and improve care, and it’s based on voluntary consent.
PessacAges 18 years+ - NCT07083960RecruitingPhase 1
Study of OM336 for low blood cell counts caused by immune system
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
Canberra, Australian Capital TerritoryAges 18–75 - NCT04968899RecruitingPhase 3
IgG IV plus prednisone versus high-dose dexamethasone for ITP
This Phase 3 study compares two ways of treating immune thrombocytopenia (ITP) to raise blood platelet counts and reduce bleeding. It tests whether IgG given through a vein plus prednisone works better (or safer) than high-dose dexamethasone.
CréteilAges 18–80 - NCT05152238Recruiting
ITP registry and optional blood sample collection study
This study helps doctors better understand immune thrombocytopenia (ITP) by collecting basic patient information and, if you agree, storing blood samples. It may help future care decisions and research for people with ITP.
AachenAges 18 years+ - NCT05522465RecruitingPhase 4
Steroid treatment for children with ITP to raise platelets
This trial studies a short, high-dose steroid plan (prednisone plus dexamethasone) to treat immune thrombocytopenia (ITP) in children and raise low platelet counts. It may help reduce bleeding risk while using an approach tested in children soon after diagnosis.
Fujian, FujianAges 4 weeks–14 years - NCT05694325Recruiting
Studying biologic features in adults with newly diagnosed ITP
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
BolognaAges 18 years+ - NCT05937828Recruiting
Caring for children with autoimmune blood disorders in France
This study follows children and teens who have certain autoimmune blood conditions to better understand their illness. It may help doctors learn how these conditions behave over time and improve care.
AmiensAges Up to 17 years - NCT06556888Recruiting
ITP observatory in the Brest region
This study is an observatory in the Brest region of France that collects information from people with ITP (immune thrombocytopenia) to better understand the condition. You may be eligible if you have ITP and are willing to share your experience.
Brest, Brittany RegionAges Any age - NCT06577909RecruitingPhase 2
Prednisone with or without IVIg for ITP in pregnancy
This trial compares two treatments for pregnant women with ITP (immune thrombocytopenia) and low platelet counts. It tests whether adding IVIg (immune globulin) to standard prednisone (steroid) therapy is more effective than prednisone alone.
Beijing, Beijing MunicipalityAges 18–50 - NCT06658834RecruitingPhase 2
Romiplostim for newly diagnosed ITP in adults
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06686927RecruitingPhase 2
Steroids, IVIG, and romiplostim for severe ITP
This study tests a combination of three treatments—steroids, IVIG, and romiplostim (Nplate)—for adults with severe, newly diagnosed ITP that hasn't responded well to standard therapy. The goal is to see if this triple therapy can quickly raise platelet counts and stop bleeding.
Wuhan, HubeiAges 18–75 - NCT06727669Recruiting
Long-term study of blood clotting and bleeding disorders
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
Beijing, Beijing MunicipalityAges Any age - NCT06888960RecruitingEarly Phase 1
Testing CC312 for people with autoimmune diseases
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Tianjin, ChinaAges 18 years+ - NCT06943937RecruitingPhase 1
Cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy (YTS109 cells) for people with severe lupus that hasn't been controlled by standard treatments. The goal is to see if these cells can help calm the immune system and improve lupus symptoms.
Beijing, Beijing MunicipalityAges 18–65 - NCT07093606Recruiting
Eltrombopag and liver function in ITP patients
This study looks at how the drug eltrombopag affects the liver in people with primary ITP (immune thrombocytopenic purpura), a condition where the immune system destroys platelets. It aims to check if liver problems develop during treatment and who might be at higher risk.
SohagAges 18–75 - NCT07104565RecruitingPhase 2
Tafasitamab for autoimmune blood cell disorders
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Glendale, ArizonaAges 18 years+ - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07175493RecruitingPhase 1/Phase 2
CM336 for relapsed or refractory autoimmune cytopenia
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
Zhengzhou, HenanAges 18 years+
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune thrombocytopenia?
- Yes. Clin2 currently lists 93 recruiting immune thrombocytopenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune thrombocytopenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune thrombocytopenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.